Mana.bio Unveils Mina™, the World’s First LLM-Powered AI Agent for Lipid Nanoparticles

Mana.bio, a biotechnology company pioneering the intersection of artificial intelligence and RNA delivery, today announced the launch of Mina™, the world’s first large-language-model (LLM) built specifically for lipid nanoparticles (LNPs). Mina — described as a “ChatGPT for LNPs” — is publicly available at no cost, marking a significant step forward in accelerating scientific discovery and advancing the future of gene therapy and RNA-based medicines.

Mina gives scientists access to curated data, predictive modeling, and optimized formulation insights — empowering them to accelerate discovery, reduce barriers to innovation, and pursue novel therapies with greater precision and confidence. Mina supports researchers and scientific professionals with features for experimentation, data analysis, and LNP design.

While Mana.bio retains exclusive access to its most advanced predictive models and proprietary datasets, the company is committed to collaborating with partners interested in leveraging Mina’s full platform capabilities.

Read the full article here

Explore Mina™ here for free here